A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

City Therapeutics, Inc. announced its launch today with a vision to lead the future of RNA interference (RNAi)-based medicine. City Therapeuticstm aims to harness next-generation engineering of small ...

The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

[28] RNA interference (RNAi) is a naturally occurring biological pathway in which small, double-stranded RNA molecules suppress gene expression in an exquisitely sequence-specific manner Exogenous ...

MIT study reveals 5-fluorouracil functions by disrupting RNA, not DNA, potentially impacting cancer treatment.

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

In the late 1980s, Ambros and Ruvkun were postdoctoral researchers in the laboratory of Robert Horvitz, who received the ...

Nobel Prize for Physiology awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in ...

Victor Ambros, on the UMass faculty since 2008, and Gary Ruvkun, of Massachusetts General Hospital and Harvard Medical School ...

Development programmes that leverage an approach called RNA interference (RNAi) are breaking this mould, accelerating the design process for new drug candidates while also improving the odds of ...

MicroRNAs, or miRNAs, are small, non-coding molecules of RNA. They play an important role in determining how much messenger RNA (mRNA), which carries genetic information, eventually gets translated ...